Fenwick received multiple top honors at Euromoney’s LMG Life Sciences 2025 Americas Awards, taking home M&A Firm of the Year, Venture Capital Firm of the Year, and the Impact Deal of the Year Award for our representation of Alpine Immune Sciences in its $4.9 billion acquisition by Vertex Pharmaceuticals. Doug Cogen was also named M&A Attorney of the Year for his work advising on market-shaping transactions across the sector.
The awards spotlight Fenwick’s role in shaping landmark industry deals, such as Shockwave Medical’s $13.1 billion acquisition by Johnson & Johnson and Vertex’s $4.9 billion acquisition of Alpine Immune Sciences, which was recognized as Impact Deal of the Year for its potential to advance treatments for autoimmune diseases. Both transactions were led by Cogen, whose counsel helped guide these complex, high-value deals to successful close.
As Venture Capital Firm of the Year, Fenwick has recently advised on 180+ life sciences venture financing transactions totaling more than $4 billion in cumulative value.
In addition, Fenwick was shortlisted in several categories, highlighting the firm’s IP and litigation work on notable matters, such as advising Formation Bio’s multiyear drug development partnership with OpenAI and Sanofi and representing Meril in high-stakes patent litigation, securing a result that preserved the company’s U.S. market position.
In total, Fenwick was shortlisted in 12 categories, including both firmwide and individual recognitions for this work:
Firm
Individuals
To see the full list of 2025 Americas Awards winners, visit the LMG Life Sciences website.